Sharps Technology Provides Update on Commercialization Activities and is Highlighted in Med Tech Outlook Feature Article

Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces an

Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces an update on commercialization activities and is highlighted in Med Tech Outlook feature article.

Med Tech Outlook named Sharps Technology, Inc. the “Top Safety Syringe Manufacturer in 2023” and featured the Company in a cover article in the July edition of the publication, which can be found HERE. The article, entitled “Sharps Technology, Inc.: Modernizing Drug Delivery with Novel Safety Syringe System Innovations”, reviews the Company’s technology offerings, transformative partnership with Nephron Pharmaceuticals, its next generation polymer-based prefillable syringe systems, and strategy forward with commercialization. Sharps was privately founded in 2017 with a vision to develop innovative drug delivery technology, and the Company is now advancing its products from research and development to commercial sales that are expected to launch in 2023.

Total
0
Shares
Related Posts